Ocrevus 300mg Injection

About

Ocrevus (ocrelizumab) is a humanized monoclonal antibody that selectively targets CD20-positive B lymphocytes, which are believed to play a key role in the pathogenesis of multiple sclerosis (MS). By depleting these specific B cells, Ocrevus reduces inflammation and nerve damage in the central nervous system, thereby slowing disease activity. It is approved for the treatment of both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), representing a significant advancement in MS therapy. Administered via intravenous infusion, ocrelizumab works by modulating the immune system to significantly reduce relapse rates, slow the progression of disability, and decrease the formation of new brain lesions. Its targeted action offers a distinct therapeutic approach for managing the chronic and debilitating nature of MS, providing a crucial option for patients with these forms of the disease.

Uses

• Relapsing-remitting multiple sclerosis (RRMS)
• Primary progressive multiple sclerosis (PPMS)
• Reducing frequency of MS relapses
• Slowing progression of disability in MS

Directions For Use

Administered via intravenous infusion by a healthcare professional. Pre-medication is typically given to reduce infusion-related reactions.

Benefits

• Effective for both RRMS and PPMS
• Significantly reduces relapse rates
• Slows disability progression
• Convenient dosing schedule (twice yearly)
• Well-tolerated by many patients
• Targets a key immune pathway in MS

Side Effects

• Infusion-related reactions (e.g., rash, itching, fever)
• Upper respiratory tract infections
• Skin infections
• Herpes infections
• Headache
• Nausea
• Diarrhea
• Back pain
• Urinary tract infections
• Progressive multifocal leukoencephalopathy (PML, rare)
• Increased risk of malignancies (rare)
• Neutropenia (low white blood cells)

Safety Measures

• Alcohol - No specific contraindication with alcohol. However, excessive alcohol consumption may impair immune function, which is relevant for an immunosuppressant.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm. Use effective contraception during and for at least 6 months after the last dose.
• Breastfeeding - Avoid breastfeeding during treatment and for at least 6 months after the last dose, as the drug may be excreted in breast milk.
• Liver - No specific dose adjustment required for liver impairment, but use with caution and monitor liver function.
• Kidney - No specific dose adjustment required for kidney impairment, but use with caution and monitor kidney function.
• Lung - Monitor for respiratory infections, as immunosuppression can increase susceptibility. Rare cases of interstitial lung disease have been reported.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.